In a settlement of False Claims Act lawsuits initiated by whistleblowers, Par Pharmaceutical Companies Inc. agreed to pay $45 million to resolve criminal and civil liability for improper marketing practices.
The settlement resolves allegations that Par promoted the prescription drug Megace ES for uses that had not been approved by the Food and Drug Administration, and caused false claims to be submitted to federal government programs.
As a part of the settlement, the whistleblowers who exposed Par’s improper marketing conduct will receive $4.4 million.
For more information on this case, click here: http://www.justice.gov/opa/pr/2013/March/13-civ-270.html